MedTrace Logo

Dermatopharmacokinetic Trial of LEO 90100 Foam

NCT03476746 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-02-24

No results posted yet for this study

Summary

This is a phase 1, single centre trial in Japanese healthy male subjects comparing the amount of active ingredients of LEO 90100 foam and Dovobet® ointment in the stratum corneum.

Conditions

  • Healthy

Interventions

DRUG

LEO 90100 foam

A foam formulation of the active comparator Dovobet® ointment

DRUG

Dovobet® ointment

Ointment formulation containing same active ingredients as LEO 90100 foam

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Study Director · LEO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2018-07-01
Completion
2018-07-01

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476746 on ClinicalTrials.gov